公开(公告)号：US06596543B2

公开(公告)日：2003-07-22

申请号：US09815398

申请日：2001-03-22

申请人： Jianfang Wang ,  Kevin Bruce Johnson ,  Liliana Maria Tejidor ,  Hema Doobay

发明人： Jianfang Wang ,  Kevin Bruce Johnson ,  Liliana Maria Tejidor ,  Hema Doobay

IPC分类号： G01N3386

CPC分类号： A61K9/127

摘要： The present invention relates generally to the field of prothrombin time reagents for determining dysfunction in the coagulation system and more specifically to reagents made from native thromboplastin or purified or recombinant tissue factor and phospholipids from a natural or synthetic source. The present invention relates to methods to make a diagnostic reagent that includes a membrane-bound protein incorporated into a liposome and having additional empty liposomes (liposomes without membrane-bound protein incorporated therein) added to the solution.

公开(公告)号：US20050191751A1

公开(公告)日：2005-09-01

申请号：US10663872

申请日：2003-09-16

申请人： Liliana Tejidor ,  Trevor Baglin ,  Hema Doobay ,  Roger Luddington ,  Timothy Fischer

发明人： Liliana Tejidor ,  Trevor Baglin ,  Hema Doobay ,  Roger Luddington ,  Timothy Fischer

IPC分类号： G01N33/48 ,  C12Q1/56 ,  G01N33/86 ,  G01N31/00

CPC分类号： G01N33/86 ,  Y10T436/10

摘要： A reagent and kit are disclosed for determining if a patient is hypercoagulable, hypocoagulable or normal. The test involves providing a test sample from the patient and initiating coagulation in the sample in the presence of an activator, which is added to the sample in an amount which will result in intrinsic tenase-dependent fibrin. Then the formation of the intrinsic tenase-dependent fibrin polymerization is monitored over time so as to derive a time-dependent profile, with the results of the fibrin polymerization monitoring determining whether the patient is hypercoagulable, normal or hypocoagulable. The coagulation activator is added in an amount that triggers a thrombin explosion that is dependent on the propagation phase and amplification pathways. In this way, a single assay can assess the hemostatic potential of a sample.

摘要翻译： 公开了一种试剂和试剂盒，用于确定患者是否是高凝状态，低凝或正常。 该试验涉及提供来自患者的测试样品并在活化剂存在下引发样品中的凝结，其以一定量导致固有的依赖于tenase的纤维蛋白加入到样品中。 然后，随着时间的推移监测固有的tenase依赖性纤维蛋白聚合的形成，从而导出时间依赖性分布，纤维蛋白聚合监测的结果确定患者是否是高凝状态，正常或低凝状态。 加入的凝血活化剂的量会触发依赖于繁殖期和扩增途径的凝血酶爆发。 以这种方式，单个测定可以评估样品的止血电位。

公开(公告)号：US06645768B1

公开(公告)日：2003-11-11

申请号：US09698589

申请日：2000-10-27

申请人： Liliana Tejidor ,  Trevor Baglin ,  Hema Doobay ,  Roger Luddington ,  Timothy J. Fischer

发明人： Liliana Tejidor ,  Trevor Baglin ,  Hema Doobay ,  Roger Luddington ,  Timothy J. Fischer

IPC分类号： G01N3386

CPC分类号： G01N33/86 ,  Y10T436/10

摘要： A reagent and kit are disclosed for determining if a patient is hypercoagulable, hypocoagulable or normal. The test involves providing a test sample from the patient and initiating coagulation in the sample in the presence of an activator, which is added to the sample in an amount which will result in intrinsic tenase-dependent fibrin. Then the formation of the intrinsic tenase-dependent fibrin polymerization is monitored over time so as to derive a time-dependent profile, with the results of the fibrin polymerization monitoring determining whether the patient is hypercoagulable, normal or hypocoagulable. The coagulation activator is added in an amount that triggers a thrombin explosion that is dependent on the propagation phase and amplification pathways. In this way, a single assay can assess the hemostatic potential of a sample.

摘要翻译： 公开了一种试剂和试剂盒，用于确定患者是否是高凝状态，低凝或正常。 该试验涉及提供来自患者的测试样品，并在活化剂存在下引发样品中的凝血，其以一定量导致固有的依赖于tenase的纤维蛋白加入到样品中。 然后，随着时间的推移监测内在的tenase依赖性纤维蛋白聚合的形成，从而导出时间依赖性分布，纤维蛋白聚合监测的结果确定患者是否是高凝状态，正常或低凝状态。 加入的凝血活化剂的量会触发依赖于繁殖期和扩增途径的凝血酶爆发。 以这种方式，单个测定可以评估样品的止血电位。